Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Stomach Neoplasms 2Melanoma 2Advanced Solid Tumors 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma of the Stomach 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × tesetaxel × Clear all
NCT01573468 2012-07-24

TESEGAST

Genta Incorporated

Phase 2 Unknown
580 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01348009 2012-03-13

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Genta Incorporated

Phase 1/2 Unknown
63 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡